Expand BMRN Menu
BMRN MENU

BMRN Latest Press Releases

-- July 13, 2026 --

U.S. Food and Drug Administration Accepts BioMarin's Supplemental New Drug Application for Full Approval of VOXZOGO (vosoritide) for Children With Achondroplasia PRNewswire 9:05 AM

-- June 16, 2026 --

BioMarin Announces New Three-Year VOXZOGO (vosoritide) Data in Hypochondroplasia and BMN 333 Early Results at ENDO 2026 PRNewswire 9:05 AM

-- May 20, 2026 --

BioMarin Announces Positive Phase 3 Pivotal Study Results for VOXZOGO (vosoritide) in Children with Hypochondroplasia PRNewswire 4:20 PM

-- May 18, 2026 --

BioMarin Provides Update on Phase 3 Trial for BMN 401 in Children Aged 1-12 With ENPP1 Deficiency PRNewswire 9:05 AM

-- May 5, 2026 --

4D Path Announces Strategic Financing and Appointment of Katherine Vega Stultz and Robert J. Hombach to Its Board of Directors Business Wire 7:00 AM

-- May 4, 2026 --

BioMarin Reports First Quarter 2026 Financial and Operating Results PRNewswire 4:05 PM

-- May 2, 2026 --

BioMarin Presents New Data on the Effect of Long-Term Treatment with VOXZOGO (vosoritide) on Arm Span, Bone Health and Growth in Children With Achondroplasia at the Pediatric Endocrine Society's 2026 Annual Meeting PRNewswire 3:30 PM

-- April 27, 2026 --

BioMarin Completes Acquisition of Amicus Therapeutics PRNewswire 8:44 AM

-- April 21, 2026 --

BioMarin Announces Board Leadership Transition PRNewswire 4:24 PM

-- March 12, 2026 --

BioMarin Presents New Data on the Positive Impact of Early Treatment With VOXZOGO (vosoritide) on Proportionality and Arm Span in Children with Achondroplasia at the 2026 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting PRNewswire 9:05 AM

-- February 27, 2026 --

U.S. Food and Drug Administration Approves BioMarin's PALYNZIQ (pegvaliase-pqpz) for Adolescents 12 Years of Age and Older with Phenylketonuria (PKU) PRNewswire 8:00 PM
Market Data Delayed 15 Minutes